Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Rome, IT · Author affiliation
From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health–Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D...Location evidence
Toulouse, FR · Author affiliation
From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health–Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D...Location evidence
A plain-language reading has not been prepared for this paper yet.